Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Deffered Revenue (2023 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Deffered Revenue over the past 3 years, most recently at $4.9 million for Q4 2024.

Quarterly results put Non-Current Deffered Revenue at $4.9 million for Q4 2024, up 1420.25% from a year ago — trailing twelve months through Nov 2024 was $4.9 million (up 1420.25% YoY), and the annual figure for FY2024 was $4.7 million, up 59.97%.
Non-Current Deffered Revenue for Q4 2024 was $4.9 million at Lifecore Biomedical, Inc. \De\, up from $4.8 million in the prior quarter.
Over the last five years, Non-Current Deffered Revenue for LFCR hit a ceiling of $4.9 million in Q4 2024 and a floor of $321000.0 in Q4 2023.